Oxaliplatin: Shows efficacy in metastatic colorectal cancer and has potential for the treatment of other malignancies

被引：0

作者：

不详

机构：

来源：

Drugs & Therapy Perspectives | 2001年 / 17卷 / 15期

关键词：

Colorectal Cancer; Adis International Limited; Irinotecan; Oxaliplatin; Metastatic Colorectal Cancer;

D O I：

10.2165/00042310-200117150-00001

中图分类号：

学科分类号：

摘要：

Oxaliplatin is a platinum compound with activity as a first- and second-line agent for the treatment of advanced colorectal cancer when combined with fluorouracil/folinic acid (leucovorin). Objective response rates of ≥50% have typically been achieved for first-line therapy and of 13 to 45% for second-line therapy. Furthermore, treatment with this combination has enabled the surgical removal of previously unresectable liver metastases. Oxaliplatin also shows promise in the treatment of other cancers, particularly advanced ovarian cancer. Oxaliplatin monotherapy resulted in response rates of 16 to 27% in patients with ovarian cancer relapsing after, or refractory to, other platinum agent therapy. These response rates were increased to 40 to 73% when used in combination with paclitaxel or cisplatin or both. Sensory neuropathy is the main cumulative dose-limiting factor in patients receiving oxaliplatin. Haematological and gastrointestinal adverse events occur frequently but are generally mild to moderate in intensity.

引用

页码：1 / 5

页数：4

共 16 条

[1]

Culy C.R., Clemett D., Wiseman L.R., Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastastic colorectal cancer and its potential in other malignancies, Drugs, 60, 4, pp. 895-924, (2000)

[2]

Royce M.E., Hoff P.M., Pazdur R., Progress in colorectal cancer chemotherapy: How far have we come, how far to go?, Drugs Aging, 17, 3, pp. 201-216, (2000)

[3]

Matheson A.J., Noble S., Management of colorectal cancer: Defining the role of raltitrexed, Dis Manage Health Outcomes, 9, 5, pp. 269-287, (2001)

[4]

(2001)

[5]

Sargent D.J., Niedzwiecki D., O'Connell M.J., Et al., Recommendation for caution with irinotecan, fluorouracil and leucovorin for colorectal cancer

[6]

Physicians' Desk Reference 2001, (2001)

[7]

de Gramont A., Figer A., Seymour M., Et al., Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J Clin Oncol, 18, 16, pp. 2938-2947, (2000)

[8]

Giacchetti S., Perpoint B., Zidani R., Et al., Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer, J Clin Oncol, 18, pp. 136-147, (2000)

[9]

Giacchetti S., Itzhaki M., Gruia G., Et al., Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery, Ann Oncol, 10, pp. 663-669, (1999)

[10]

Bismuth H., Adam R., Levi F., Et al., Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy, Ann Surg, 224, pp. 509-520, (1996)

← 1 2 →